Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides

Pharmacological modulation of p53 activity is an attractive therapeutic strategy in cancers with wild-type p53. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2, a key negative regulator of p53 and blocks its activity. We have described resistance mutations in H...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Siau Jia, Joseph, Thomas, Chee, Sharon, Li, Ling, Yurlova, Larisa, Zolghadr, Kourosh, Brown, Christopher, Lane, David, Verma, Chandra, Ghadessy, Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835680/
https://www.ncbi.nlm.nih.gov/pubmed/24278380
http://dx.doi.org/10.1371/journal.pone.0081068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835680/
https://www.ncbi.nlm.nih.gov/pubmed/24278380
http://dx.doi.org/10.1371/journal.pone.0081068

Ejemplares similares